chufangao/CTO huggingface dataset:
Clinical trial NCT04949425: A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
Official title: An Open-label, Non-randomised, Multicentre Study to Allow Continued Access to and Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours Enrolled in Adavosertib Clinical Pharmacology Studies
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study terminated because the clinical development programme for Adavosertib has been discontinued
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-09-13
Primary completion date: 2022-04-21
Completion date: 2022-04-21
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the~Disclosure Statements at:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Clinical trial NCT03398252: Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL
Official title: Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL
Sponsor: The University of Texas Health Science Center, Houston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: No funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-12
Primary completion date: 2023-10-01
Completion date: 2023-10-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02651116: Dextromethorphan Pediatric Acute Cough Study
Official title: A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP PILOT STUDY TO EVALUATE THE EFFICACY OF DEXTROMETHORPHAN HYDROBROMIDE ON ACUTE COUGH IN A PEDIATRIC POPULATION
Acronym: CHPA DXM
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The study was prematurely discontinued due to slow enrollment during the 2019/2020 cold season. No safety or efficacy concerns led to the decision to terminate
Enrollment: 131.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-02-25
Primary completion date: 2020-03-19
Completion date: 2020-03-19
Baseline population: The safety analysis set included all participants who received the study drug.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03954834: A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
Official title: A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone
Acronym: SURPASS-1
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 478.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-06-03
Primary completion date: 2020-10-05
Completion date: 2020-10-28
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT03444376: The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer
Official title: A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients With Advanced, Non-Resectable HPV Type 16 and/or 18 Positive Cervical Cancer
Sponsor: Genexine, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 65.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-06-19
Primary completion date: 2022-04-29
Completion date: 2023-12-21
Plan to share individual participant data: NO
Clinical trial NCT00581477: Treatment of Orthostatic Hypotension
Official title: Treatment of Hypotensive Patients Having a Unique Pattern of Autonomic Symptoms
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: 1. enrollment slower than anticipated; 2. FDA approval of droxidopa so no longer need to treat patients on research basis; 3. personnel who were primarily responsible for the study are no longer at Vanderbilt.
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2004-01-31
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Clinical trial NCT04154787: Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy
Official title: A Randomized, Open-label, Two Arm, Parallel Group, Proof-of-concept Clinical Trial to Investigate the Efficacy and Safety of LNP023 Compared With Rituximab in the Treatment of Subjects With Idiopathic Membranous Nephropathy
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 37.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-23
Primary completion date: 2023-01-20
Completion date: 2023-01-20
Limitations and caveats: Per protocol, participants randomized to the former LNP023 low dose arm (LNP023 10/50 mg b.i.d.) were included in the safety and PK analyses but not in the PD/efficacy analyses as the low number of subjects would not have allowed for a meaningful analysis and interpretation of PD/efficacy data.
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT02436226: Use of Low Dose of HCG During Ovulation Induction With CC in Women With CC Resistant PCOS
Official title: Use of Low Dose of Human Chorionic Gonadotropin During Ovulation Induction With Clomiphene Citrate in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome
Sponsor: Mansoura University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 300.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-03-31
Primary completion date: 2023-01-31
Completion date: 2023-01-31
Plan to share individual participant data: NO
Clinical trial NCT05141357: A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer
Official title: A Phase 2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination With Pembrolizumab for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Acronym: HBI-8000
Sponsor: HUYABIO International, LLC. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow Recruitment
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-03-14
Primary completion date: 2023-04-19
Completion date: 2023-04-19
Clinical trial NCT03597464: Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin
Official title: A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Voclosporin (23.7 mg Twice Daily) With Placebo in Subjects With Lupus Nephritis
Acronym: AURORA 2
Sponsor: Aurinia Pharmaceuticals Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 216.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-29
Primary completion date: 2021-10-07
Completion date: 2021-10-07
Baseline population: Intent-to-Treat is comprised of all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for subjects that continued in AURORA 2. Intent-to-Treat population was used for analysis of all Outcome Measures. Safety population comprised all randomized subjects who took at least one dose of study treatment, and was used for AE and SAE reporting.
Plan to share individual participant data: NO
Clinical trial NCT02993406: Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
Official title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant
Acronym: CLEAR Outcomes
Sponsor: Esperion Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 13970.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-22
Primary completion date: 2022-11-07
Completion date: 2022-11-07
Baseline population: Intention-to-Treat Population is defined as all randomized participants.
Plan to share individual participant data: NO
Clinical trial NCT04256174: A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis
Official title: A Phase 1, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AK120 in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis
Sponsor: Akeso (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 80.0 (ACTUAL)
Number of arms: 9.0
Start date: 2020-06-15
Primary completion date: 2021-10-29
Completion date: 2021-10-29
Plan to share individual participant data: NO
Clinical trial NCT05497284: To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF
Official title: A Participant- and Investigator-blinded, Randomized, Placebo-controlled, Multicenter, Platform Study to Investigate Efficacy, Safety, and Tolerability of Various Single Treatments in Participants With Idiopathic Pulmonary Fibrosis
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor Decision
Enrollment: 46.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-11-10
Primary completion date: 2024-08-26
Completion date: 2024-09-26
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03008070: Phase 2b Study in NASH to Assess IVA337
Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-range, Proof-of-concept, 24-week Treatment Study of IVA337 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)
Acronym: NATIVE
Sponsor: Inventiva Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 247.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-02-07
Primary completion date: 2020-02-20
Completion date: 2020-03-16
Clinical trial NCT04655807: A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease
Official title: A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Proof-of-Concept Clinical Study to Evaluate the Safety and Efficacy of JNJ-64304500 as Add-on Therapy to Standard of Care Biologic Therapy With Anti-Tumor Necrosis Factor Alpha or Anti-Interleukin 12/23 in Responder Not Remitter Participants With Active Crohn's Disease
Acronym: DUET
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor Decision.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-03
Primary completion date: 2023-05-24
Completion date: 2023-09-04
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT03799003: A Study of ASP1951 in Subjects With Advanced Solid Tumors
Official title: A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study was terminated for lack of efficacy.
Enrollment: 119.0 (ACTUAL)
Number of arms: 11.0
Start date: 2019-01-14
Primary completion date: 2023-07-06
Completion date: 2023-07-06
Plan to share individual participant data: YES
IPD sharing description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
IPD time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
IPD access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Clinical trial NCT05165732: Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19
Official title: A Randomized, Open, Control Phase ⅠV Clinical Trial, to Evaluate One Booster Immunization of Inactivated COVID-19 Vaccine (CoronaVac) or Original Vaccine in Adults Aged 18-45 Years Old Previously Vaccinated With Inactivated COVID-19 Vaccine From Difference Manufactures
Sponsor: Sinovac Biotech Co., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: SUSPENDED 
Why stopped: Limited subjects
Enrollment: 480.0 (ESTIMATED)
Number of arms: 5.0
Start date: 2022-12-20
Primary completion date: 2023-03-20
Completion date: 2023-08-20
Clinical trial NCT03839940: Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
Official title: Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention Versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)
Acronym: MIST
Sponsor: Alliance for Clinical Trials in Oncology (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Severe lack of accrual
Enrollment: 39.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-15
Primary completion date: 2020-12-17
Completion date: 2020-12-17
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04848480: A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
Official title: Efficacy and Safety of Once Weekly Insulin Icodec Compared to Once Daily Insulin Degludec 100 Units/mL, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes. A 26-week, Randomised, Multicentre, Open-label, Active-controlled, Parallel Group, Two Armed, Treat-to-target Trial Investigating the Effect on Glycaemic Control and Safety of Treatment With Once Weekly Insulin Icodec Compared to Once Daily Insulin Degludec, Both in Combination With Insulin Aspart in Adults With Type 1 Diabetes, With a 26-week Extension Investigating Long Term Safety
Acronym: ONWARDS 6
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 582.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-30
Primary completion date: 2022-04-28
Completion date: 2022-12-02
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT01865747: A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Official title: A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy
Acronym: METEOR
Sponsor: Exelixis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 658.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-06-30
Primary completion date: 2015-05-22
Completion date: 2021-01-15
Clinical trial NCT03348735: Localized Neuropathic Pain: Topical Treatment Versus Systemic Treatment
Official title: Safety, Efficacy and Patient Acceptability of Topical Treatment Versus Systemic Treatment: a Randomized, Multicentre, Comparative Pragmatic Trial in Adult Patients Suffering From Diverse Localized Neuropathic Pain (LNP) Syndromes
Acronym: PELICAN
Sponsor: University Hospital, Antwerp (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Low inclusion rate
Enrollment: 33.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-12-03
Primary completion date: 2021-04-19
Completion date: 2021-04-19
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03714828: Study of TVEC in Patients With Cutaneous Squamous Cell Cancer
Official title: A Single Arm Phase 2 Study of Talimogene Laherparepvec in Patients With Cutaneous Squamous Cell Cancer
Sponsor: University of Arizona (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-20
Primary completion date: 2023-07-19
Completion date: 2023-07-19
Clinical trial NCT03500874: Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM
Official title: Adjuvant Systemic Chemotherapy With or Without Hepatic Arterial Infusion Using Floxuridine in Patients Following Colorectal Cancer Liver Metastases Resection
Sponsor: Sun Yat-sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was terminated prematurely due to FUDR production halt in China
Enrollment: 92.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-28
Primary completion date: 2021-08-31
Completion date: 2021-08-31
Plan to share individual participant data: UNDECIDED
IPD sharing description: Study Protocol
Clinical trial NCT05243719: Open-label Extension Study of ADP101
Official title: An Open-Label Extension Study Evaluating the Safety and Efficacy of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (The Encore Study)
Sponsor: Alladapt Immunotherapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 45.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-03-14
Primary completion date: 2024-02-27
Completion date: 2024-02-27
Plan to share individual participant data: NO
Clinical trial NCT05879120: Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab with and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma
Official title: Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab with and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: PI Request
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-07-30
Primary completion date: 2024-10-02
Completion date: 2024-10-02
Plan to share individual participant data: NO
Clinical trial NCT05084859: A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Official title: A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Sponsor: Biosplice Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study was terminated due business reasons by Sponsor.
Enrollment: 30.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-11-03
Primary completion date: 2022-10-20
Completion date: 2022-10-20
Plan to share individual participant data: NO
Clinical trial NCT03901638: Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy
Official title: Gut Microbiota Alteration and Improvement of Ataxia in Patients of Multiple System Atrophy Treating With Tllsh2910 - a Randomized, Placebo-controlled, Double-blinded, Cross-over, Single-center Clinical Trial
Sponsor: National Taiwan University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Project replanning
Enrollment: 18.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-02
Primary completion date: 2023-04-03
Completion date: 2023-04-03
Plan to share individual participant data: NO